| Name | Title | Contact Details |
|---|---|---|
Anthony Mancini |
Executive Vice President and Chief Operating Officer | Profile |
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation.
RetinaPharma Technologies is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.
BioCatalyst International is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Diagnostic Group is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.